Pasar al contenido principal

Translational Research in Airway Diseases: Novel Biomarkers and Pathogenesis Mechanisms of Different Asthma Phenotypes

RYC2021-032676-I

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Desarrollar, Atraer y Retener Talento
Subprograma Subprograma Estatal de Incorporación
Convocatoria Ramón y Cajal
Año convocatoria 2021
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDADE DE SANTIAGO DE COMPOSTELA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publicación Artículo científico (JournalArticle)

Novel therapeutic strategies for atopic dermatitis: Biomarker modulation and clinical implications. A systematic review

  • Moreiras Arias, Noelia
  • Nieto Fontarigo, Juan José
  • Salgado Castro, Francisco Javier
  • González Vilas, Daniel
  • Paredes Suárez, Carmen
  • Combo García, Enma
  • Rodríguez Otero, Carmen
  • Flórez, Ángeles
Advances in the understanding of atopic dermatitis (AD) pathogenesis have driven the development of innovative systemic therapies targeting key immunologic pathways. This systematic review summarizes current evidence on the impact of biologic agents, Janus kinase (JAK) inhibitors, and other emerging treatments on AD-related biomarkers and their correlation with clinical outcomes. A comprehensive literature search was conducted across PubMed, Embase, Scopus, and Web of Science for studies published between 2014 and 2024. Eighty studies met the inclusion criteria. Dupilumab was the most extensively investigated therapy, followed by tralokinumab, JAK inhibitors, and novel agents such as amlitelimab, stapokibart, and tezepelumab. Across drug classes, consistent reductions in CCL17/TARC, LDH, and total IgE levels were observed, generally paralleling clinical improvement in EASI and SCORAD scores. Transcriptomic and proteomic analyses revealed normalization of Th2/Th22 inflammatory signatures and restoration of barrier-related gene expression, while microbiome studies showed a reduction in Staphylococcus aureus colonization. Despite these advances, the heterogeneity of study designs and analytical techniques limits the comparability of results. CCL17 and LDH currently represent the most reliable biomarkers associated with disease severity and treatment response, although their limited specificity restricts clinical applicability. Future research should aim to validate integrated biomarker panels combining immunologic, transcriptomic, and microbiomic data to enable precision medicine approaches in atopic dermatitis management.
Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publicación Artículo científico (JournalArticle)

Mepolizumab modifies blood eosinophil proteome and transcriptome in severe eosinophilic asthma

  • Miguéns Suárez, Pablo
  • Vázquez Mera, Sara
  • Martelo Vidal, Laura
  • Blanco Aparicio, Marina
  • Calvo Álvarez, Uxío
  • González Fernández, Coral
  • Mosteiro Añón, Mar
  • Corbacho Abelaira, Dolores
  • Hermida Valverde, Tamara
  • Calvo Henríquez, Christian
  • Bravo López, Susana Belén
  • Uller, Lena
  • Nieto Fontarigo, Juan José
  • Salgado Castro, Francisco Javier
  • González Barcala, Francisco Javier
Background Mepolizumab, an anti-IL5 monoclonal antibody, effectively reduces exacerbations and improves disease control in severe eosinophilic asthma (SEA). While this treatment rapidly decreases blood eosinophil counts, some patients continue to experience asthma symptoms, suggesting that other features beyond eosinophil number contribute to disease persistence. In this work, we aim to characterize the molecular and functional signature of circulating eosinophils in SEA in response to mepolizumab therapy. Methods We performed proteomic (LC–MS/MS) and targeted transcriptomic (Nanostring) analyses on isolated blood eosinophils from healthy individuals and SEA patients at baseline and after 4, 16 and 32 weeks of treatment with mepolizumab. Western blot was used to validate selected genes and proteins. Results Eosinophils from healthy donors and post-treatment SEA patients exhibit lower levels of proteins related to cytoskeleton (e.g., GSN, DBNL, ARPC2 and ARPC3), suggesting a lower potential for migration and tissue extravasation. Several proteins (e.g., EPX and NCF2) and genes (e.g., CCL23 and SOCS3) directly involved in eosinophil effector functions, including ROS generation and degranulation, were significantly downregulated after mepolizumab treatment. The downregulation of GSN (actin-binding protein), NCF2 (subunit of the NADPH oxidase complex) and EPX (eosinophil-specific granule protein), was further validated by western blot. Conclusions Our multi-omic analysis suggests that mepolizumab reduces the migratory capacity and effector-related molecular signatures of circulating eosinophils in SEA patients. Selected proteins, including GSN, NCF2 and EPX, may serve as candidate biomarkers for monitoring response to therapy